[go: up one dir, main page]

MX387675B - Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona. - Google Patents

Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona.

Info

Publication number
MX387675B
MX387675B MX2018016387A MX2018016387A MX387675B MX 387675 B MX387675 B MX 387675B MX 2018016387 A MX2018016387 A MX 2018016387A MX 2018016387 A MX2018016387 A MX 2018016387A MX 387675 B MX387675 B MX 387675B
Authority
MX
Mexico
Prior art keywords
crystalline salts
immunoproteasome inhibitor
epoxyketone
peptide
epoxyketone peptide
Prior art date
Application number
MX2018016387A
Other languages
English (en)
Other versions
MX2018016387A (es
Inventor
Dustin Mcminn
Evan Lewis
Henry Johnson
Sean Dalziel
Original Assignee
Kezar Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kezar Life Sciences filed Critical Kezar Life Sciences
Publication of MX2018016387A publication Critical patent/MX2018016387A/es
Publication of MX387675B publication Critical patent/MX387675B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)

Abstract

En la presente se proporciona un inhibidor de inmunoproteasoma de péptido epoxicetona, que tiene una estructura: Fórmula (I) DONDE X- es un contraión, formas cristalinas, sales, y procesos para obtenerlos, y sus formulaciones. VER FORMULA.
MX2018016387A 2016-06-29 2017-06-29 Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona. MX387675B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662356287P 2016-06-29 2016-06-29
PCT/US2017/039961 WO2018005772A1 (en) 2016-06-29 2017-06-29 Crystalline salts of peptide epoxyketone immunoproteasome inhibitor

Publications (2)

Publication Number Publication Date
MX2018016387A MX2018016387A (es) 2019-09-09
MX387675B true MX387675B (es) 2025-03-18

Family

ID=59351084

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016387A MX387675B (es) 2016-06-29 2017-06-29 Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona.

Country Status (25)

Country Link
US (3) US10836756B2 (es)
EP (1) EP3478670B1 (es)
JP (2) JP7132855B2 (es)
KR (2) KR102799236B1 (es)
CN (1) CN109863141B (es)
AU (1) AU2017290139B2 (es)
CA (1) CA3029032C (es)
CL (1) CL2018003872A1 (es)
DK (1) DK3478670T3 (es)
EA (1) EA201990154A1 (es)
ES (1) ES2944958T3 (es)
FI (1) FI3478670T3 (es)
HR (1) HRP20230533T1 (es)
HU (1) HUE062106T2 (es)
IL (1) IL263738B2 (es)
LT (1) LT3478670T (es)
MX (1) MX387675B (es)
PL (1) PL3478670T3 (es)
PT (1) PT3478670T (es)
RS (1) RS64286B1 (es)
SG (1) SG11201811507YA (es)
SI (1) SI3478670T1 (es)
SM (1) SMT202300145T1 (es)
TW (1) TWI751178B (es)
WO (1) WO2018005772A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX2021003899A (es) 2018-10-04 2021-06-04 Kezar Life Sciences Formulaciones de inhibidores de inmunoproteasomas.
WO2024140736A1 (zh) * 2022-12-27 2024-07-04 上海美悦生物科技发展有限公司 三肽环氧酮化合物、药物组合物及其制备方法和用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
WO1998010779A1 (en) 1996-09-13 1998-03-19 New York University Method for treating parasitic diseases with proteasome inhibitors
EP1565193B1 (en) 2002-11-06 2013-04-24 Dana-Farber Cancer Institute, Inc. Compositions for treating cancer using proteasome inhibitor PS-341
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
US7691852B2 (en) 2006-06-19 2010-04-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
RS54847B2 (sr) 2007-10-04 2019-09-30 Onyx Therapeutics Inc Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto-epoksida
CN101525370A (zh) 2008-03-06 2009-09-09 海南建邦制药科技有限公司 一种新型高效多肽合成缩合剂
JP5675629B2 (ja) 2008-10-21 2015-02-25 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンを用いた併用療法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
WO2011136905A2 (en) 2010-04-07 2011-11-03 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
US8609610B2 (en) 2011-02-18 2013-12-17 Trustees Of Dartmouth College Inhibitors of the trypsin-like site of the proteasome and methods of use thereof
ES2543923T3 (es) 2011-05-02 2015-08-25 Gilead Sciences, Inc. Sales sólidas amorfas de Cobicistat (GS-9350)
MX364393B (es) 2012-05-08 2019-04-24 Onyx Therapeutics Inc Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico.
CN104411682B (zh) 2012-06-29 2016-11-16 日产化学工业株式会社 用于制备立体选择性环氧酮化合物的方法
BR112015008160A2 (pt) 2012-10-11 2017-07-04 Hoffmann La Roche inibidores de imunoproteassoma de cetoamida
JP2015536913A (ja) 2012-10-12 2015-12-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 大環状ケトアミド免疫プロテアソーム阻害薬
SMT201700505T1 (it) * 2013-03-14 2017-11-15 Onyx Therapeutics Inc Tripeptidi inibitori delle proteasi di epossichetoni
EA030957B1 (ru) 2013-03-14 2018-10-31 Оникс Терапьютикс, Инк. Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
CN104710507B (zh) 2013-12-11 2018-08-14 深圳翰宇药业股份有限公司 一种卡非佐米的制备方法

Also Published As

Publication number Publication date
IL263738B1 (en) 2023-05-01
TWI751178B (zh) 2022-01-01
EP3478670B1 (en) 2023-04-05
LT3478670T (lt) 2023-05-25
JP2019527205A (ja) 2019-09-26
BR112018077390A2 (pt) 2019-04-09
PT3478670T (pt) 2023-05-24
KR20190026797A (ko) 2019-03-13
HRP20230533T1 (hr) 2023-08-04
JP2022106971A (ja) 2022-07-20
AU2017290139A1 (en) 2019-01-17
WO2018005772A1 (en) 2018-01-04
EP3478670A1 (en) 2019-05-08
MX2018016387A (es) 2019-09-09
CN109863141A (zh) 2019-06-07
US10836756B2 (en) 2020-11-17
US20210032232A1 (en) 2021-02-04
TW201800398A (zh) 2018-01-01
PL3478670T3 (pl) 2023-07-24
CN109863141B (zh) 2023-09-15
CA3029032C (en) 2024-10-29
CA3029032A1 (en) 2018-01-04
SMT202300145T1 (it) 2023-07-20
DK3478670T3 (da) 2023-05-15
ES2944958T3 (es) 2023-06-27
KR20240046315A (ko) 2024-04-08
SI3478670T1 (sl) 2023-06-30
US11479548B2 (en) 2022-10-25
FI3478670T3 (fi) 2023-05-04
IL263738B2 (en) 2023-09-01
IL263738A (en) 2019-01-31
KR102799236B1 (ko) 2025-04-23
US11891383B2 (en) 2024-02-06
RS64286B1 (sr) 2023-07-31
HUE062106T2 (hu) 2023-09-28
AU2017290139B2 (en) 2021-09-16
US20230106656A1 (en) 2023-04-06
SG11201811507YA (en) 2019-01-30
US20190308961A1 (en) 2019-10-10
JP7132855B2 (ja) 2022-09-07
KR102655020B1 (ko) 2024-04-04
CL2018003872A1 (es) 2019-07-19
EA201990154A1 (ru) 2019-06-28

Similar Documents

Publication Publication Date Title
DK3873903T3 (da) Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
CO2019010035A2 (es) Síntesis de inhibidor de mcl-1
EP4434979A4 (en) KIF18A INHIBITOR
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
MX2017010667A (es) Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de unso.
CO2020001861A2 (es) Inhibidores de ror gamma
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
EP4332103A4 (en) ATR INHIBITOR COMPOUND CONTAINING A SULFOXIMINE
MX2019010642A (es) Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
AR105967A1 (es) Sales de un inhibidor de pim quinasa
MX2016013162A (es) Proceso para la fabricacion de medicamentos.
MX2019010643A (es) Formas y composiciones de un inhibidor de proteina cinasa 2 activada por la proteina cinasa activada por mitogeno (mk2).
DK3470409T3 (da) Benzotriazol-afledt Alfa- og Beta-umættet amidforbindelse anvendt som TGF-BRI-hæmmer
DOS2021000191S (es) Etiqueta (ornamentación para)
IL287736A (en) Diamondoid compounds
MX387675B (es) Sales cristalinas de inhibidor de inmunoproteasoma de peptido epoxicetona.
IL283182A (en) Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
CL2020000190A1 (es) Inhibidores de ror-gamma.
IL282454A (en) Crystalline salts of a plasma kallikrein inhibitor
MX2018004979A (es) Compuesto piranodipiridinico.
DOP2022000027A (es) Síntesis de un inhibidor de calicreína plasmática a escala de proceso
AR104935A1 (es) Formas cristalinas de un inhibidor de histona deacetilasa
EP4168398A4 (en) TYK-2 INHIBITOR
CL2022003052A1 (es) Síntesis de productos intermedios de sulfonamida
IL279419A (en) Ccl5 inhibitors